萎胃康治疗慢性萎缩性胃炎的疗效及对血液流变学的影响

Therapeutic effect in chronic atrophic gastritis with Weiweikang(萎胃康) and its effect on hemorrheology

目的 :观察自拟萎胃康治疗慢性萎缩性胃炎 (CAG)的疗效及对血液流变学的影响。方法 :将 15 7例 CAG患者随机分为治疗组 (97例 )和对照组 (6 0例 )。治疗组服用萎胃康 ,对照组服用胃乐宁和多酶片。服用1个疗程后在胃镜下进行病理活检 ,同时检测血液流变学指标。结果 :治疗组总有效率为 91.75 % ,对照组总有效率为 6 8.33% ,治疗组显著优于对照组 (P<0 .0 1)。胃黏膜腺体萎缩者治愈率治疗组 (5 5 .6 7% )显著优于对照组 (2 1.6 7% ,P<0 .0 1)。伴有肠上皮化生 (IM)和不典型增生 (ATP)者治疗组有效率 (4 8.39%、6 3.6 4 % )也优于对照组 (17.6 5 %、16 .6 7% ,P均 <0 .0 5 )。治疗组全血黏度、还原黏度、血细胞比容、聚积指数治疗前后比较均有显著性意义 (P<0 .0 1或 P<0 .0 5 )。结论 :萎胃康是治疗萎缩性胃炎较为理想的方药。

Objective: To observe the therapeutic effect in chronic atrophic gastritis(CAG) with Weiweikang(萎胃康) developed by ourself and its effect on hemorrheology. Methods: One hundred and fifty-seven patients with CAG were randomly assigned to Weiweikang group(97 patients) and the control group (60 patients). Patients in Weiweikang group were received with Weiweikang, and in the control group patients were received with Weilening(胃乐宁) and multienzyme tablets. Biopsies were made by gastroscope and hemorrheology were examined after one course. Results: The total efficacy rate of Weiweikang group (91.75 %) was better significantly than that of the control group (68.33 %, P<0.01). In Weiweikang group, the cure rate of the patients whose gastric gland was atrophing (55.67 %) was better significantly than that of the control group (21.67 %, P<0.01), and the efficacy rates of the patients who were in intestinal metaplasia(IM, 48.39 %), atypical hyperplasia(ATP, 63.64 %) were better significantly than those of the control (17.65 %, 16.67 %, both P<0.05). In Weiweikang group, the levels of whole blood viscosity(WBV), reduced viscosity(RV), hematocrit(HCT), erythrocyte aggregation index(EAI) before cure were better significantly than those after cure (P<0.01 or P<0.05). Conclusion: Weiweikang is a better recipe in treating CAG.